Overview
Legal name
EXCIVION LIMITED
Region
East of England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Excivion Limited
Vaccines : Excivion
Excivion is in the vanguard of a new pharmaceutical movement in which demographic trends mandate an affordable vaccine based approach to health. We also develop point-of-care diagnostics to facilitate the development and enhance the safety in use of vaccines.
CRN
08212445
Founded
2012
Age
11
Company events
Reference milestones and recent Companies House filing stream events.
1 event
13 Sep
2012
Incorporated
InceptionCompany registered at Companies House
Public funding
3 awards
First funded
2016
Funded years
2016, 2017, 2018
Age at first award
3 years
Projects
2018
Small Business Research Initiative
Lead participant
Clinical Development of a Zika Vaccine Avoiding Disease Enhancement
1 Feb 2018 to 31 Oct 2020
Awarded
£2,000,000
Total cost £2,000,001
The Zika pandemic is a global problem with profound consequences for nations and families that will take decades to unfold, with an estimated 2.3 billion people at high or very high risk of infection (Alaniz AJ, 2017). However, Zika does not exist in isolation and is only one cog in a complex ecosystem of virus interactions where infection (or vaccination...
2017
Small Business Research Initiative
Lead participant
A Novel Diagnostic for anti-Zika Antibodies to Inform Deployment of Zika Vaccines
1 Apr 2017 to 31 Mar 2018
Awarded
£500,000
Total cost £500,000
A NOVEL "PREGNANCY-TEST-LIKE" DIAGNOSTIC FOR ZIKA VIRUS THAT WILL ALLOW THE INTELLIGENT DEVELOPMENT AND EFFECTIVE USE OF ZIKA VACCINES The Zika epidemic is a global problem with profound consequences for nations and families that will take decades to unfold. While there is an urgent need for a new vaccine against Zika, there is a similar urgency to accura...
2016
Small Business Research Initiative
Lead participant
A Dengue/Zika Vaccine That Avoids Antibody-Dependent Enhancement
1 Sep 2016 to 31 Aug 2017
Awarded
£500,000
Total cost £500,000
The present project provides a solution to the principal problem of dengue vaccine development, wherein the use of licensed (and soon to be licensed) vaccines based on existing vaccine strategies runs the risk (in a finite number of cases) of giving rise to 'antibody dependent ehnancement' of dengue infection, making it worse rather than preventing it. En...
Product types
Small Business Research Initiative